p53 β-hydroxybutyrylation attenuates p53 activity

Kun Liu1, Fangzhou Li1, Qianqian Sun1, Ning Lin1, Haichao Han1, Kaiqiang You2, Feng Tian3, Zebin Mao1, Tingting Li2, Tanjun Tong1, Melyu Geng4, Yingming Zhao5, Wei Gu6 and Wenhui Zhao

Abstract
p53 is an essential tumor suppressor, whose activity is finely tuned by the posttranslational modifications. Previous research has reported that β-hydroxybutyrate (BHB) induces β-hydroxybutyrylation (Kbhb), which is a novel histone posttranslational modification. Here we report that p53 is modified by kbhb and that this modification occurs at lysines 120, 319, and 370 of p53. We demonstrate that the level of p53 kbhb is dramatically increased in cultured cells treated with BHB and in thymus tissues of fasted mice, and that CBP catalyze p53 kbhb. We show that p53 kbhb results in lower levels of p53 acetylation and reduced expression of the p53 downstream genes p21 and PUMA, as well as reduced cell growth arrest and apoptosis in cultured cells under p53-activating conditions. Similar results were observed in mouse thymus tissue under starvation conditions, which result in increased concentrations of serum BHB, and in response to genotoxic stress caused by γ-irradiation to activate p53. Our findings thus show that BHB-mediated p53 kbhb is a novel mechanism of p53 activity regulation, which may explain the link between ketone bodies and tumor, and which may provide promising therapeutic target for cancer treatment.

Introduction

The p53 protein is one of the most widely studied transcription factors. The TP53 gene (in mice is Trp53 gene) has long been recognized as a vitally important tumor suppressor gene because it is mutated and inactivated in more than 80% of human cancer cases. p53 acts as the core node of a complicated and finely tuned network by which it controls and regulates cellular responses to various endogenous and extraneous stressors, and maintains intracellular homeostasis and metabolism, including the maintenance of oxidative balance.

Ketone bodies are also increasingly recognized as factors that fulfill signaling roles in cellular homeostasis (reviewed in refs. 18–20). Ketone bodies are also linked to cancer. For example, they reduced pancreatic cancer growth in mouse xenograft models, and decreased the...
proliferation and viability of the highly metastatic VM-M3 cells, and prolonged the survival of VM-M3 xenograft mice. The ketone body, acetoacetate, also selectively induces HMGCL expression, enhances the interaction between BRAF V600E and MEK1, and amplifies MEK-ERK signaling to drive tumor cell proliferation and growth in melanoma. The use of ketogenic diets and calorie restriction also have therapeutic effects in human and mouse brain tumors.

β-hydroxybutyrylation (kbhb) is a novel histone BHB-mediated posttranslational modification. Histone kbhb has been detected in yeast, flies, mice, and human cells, and a total of 44 histone kbhb sites have been identified in both human cells and in mouse livers. H3K9 kbhb is enriched in active gene promoters and is associated with genes upregulated in the starvation-responsive pathway. These genes are distinct to those marked by H3K9ac or H3K4me3. In human cells, histone kbhb levels increase following treatment with BHB. Histone kbhb is also significantly induced in the mouse liver by starvation or by streptozotocin-induced diabetic ketoacidosis under conditions of increased plasma BHB levels.

Till now, kbhb has been described only in histone proteins, but none of them in nonhistone proteins, particularly in transcription factors. It is well-known that almost every kind of posttranslational modification that takes place in histones also occurs in p53 protein. Our prior evidence from mass spectrometry analysis data suggested that p53 may be β-hydroxybutyrylated. Although several posttranslational regulatory mechanisms have been described in p53, the role of kbhb in the regulation of this important tumor suppressor protein has not yet been investigated. Therefore, here we studied p53 kbhb.

Detection of p53 kbhb and acetylation inside cells
p53 kbhb was determined in 293T cells transfected with Flag-p53, Flag-p300 or CBP-HA expressing p53 were established by transfecting H1299 cells with a pTRIPZ lentiviral-inducible vector expressing a Flag-p53 fusion protein and selecting the cells with puromycin. After 24 h of transfection, the cells were treated with BHB. The protein was assayed by western blot with anti-p53 antibodies (DO-1).

Cells and cell culture
H1299, 293T and U2OS cells from ATCC were cultured in DMEM (dulbecco’s modified eagle medium), supplemented with 10% FBS (fetal bovine serum). HCT116 cells from ATCC were cultured in MCOY medium supplemented with 10% FBS.

The tetracycline-inducible p53/H1299 cell lines expressing p53 were established by transfecting H1299 cells with a pTRIPZ lentiviral-inducible vector expressing a Flag-p53 fusion protein and selecting the cells with puromycin. After 24 h of transfection, the cells were suspended, diluted and re-seeded to ensure single clone formation. More than 30 clones were selected, and the expression of p53 was evaluated in each clone by western blot with anti-p53 antibodies (DO-1).

Cells were transfected with plasmid DNA or siRNA using Lipofectamine 3000 (Invitrogen) according to the manufacturer’s protocol.

Protein purification
293T cells were transfected with plasmids containing Flag-p53, Flag-p300 or CBP-HA and cultured for 48 h. The cells were then harvested and lysed in BC500 buffer (20 mM Tris-HCl pH 7.3, 500 mM NaCl, 20% glycerol, 0.5% Triton X-100) with sonication. Anti-Flag M2 beads (for Flag-p53 and Flag-p300) or anti-HA beads (for CBP-HA) were incubated with the cell lysates overnight at 4°C. The beads were washed with BC100 buffer (20 mM Tris-HCl pH 7.3, 100 mM NaCl, 20% glycerol, 0.1% Triton X-100) three times, and the purified proteins were competitively eluted with Flag peptide (Sigma) or HA peptide (Sigma) in BC100 buffer.

Methods
Antibodies and plasmids
The following antibodies were used in western blot assays: anti-β-actin (A15), anti-Flag M2 and anti-Flag M2 agarose resin (Sigma), anti-HA (3F10), anti-HA agarose resin (Roche Applied Science), anti-p53 (DO-1, which detects the N-terminal epitope comprising amino acids 11–25), anti-p53 (full-length), anti-CBP(Cell Signaling Technology), anti-p21, anti-PUMA, anti-MDM2 (Santa Cruz), anti-Ac-K101-p53, anti-Ac-K164-p53, anti-Ac-p53 C-terminal (made in-house), anti-pan-acetylation-Lysine (Ac-K) and anti-pan β-hydroxybutyrylation-Lysine (BHB-K) (PTM BioLabs; Hangzhou, China).

Plasmids Flag-p53, Flag-p300, CBP-HA and CBP-HA mutants were from Dr. Gu’s lab.

siRNA targeting CBP and p300 (1#: 5’-GAGGUCGUU UACAUAAATT-3’; 2#: 5’-UUUAUGUAAACCCGACC UCTT-3’) and a negative control (5’-UUCUCCGAACGU GUCACGUTT-3’) were synthesized by GenePharma (China).

Cells and cell culture
H1299, 293T and U2OS cells from ATCC were cultured in DMEM (dulbecco’s modified eagle medium), supplemented with 10% FBS (fetal bovine serum). HCT116 cells from ATCC were cultured in MCOY medium supplemented with 10% FBS.

The tetracycline-inducible p53/H1299 cell lines expressing p53 were established by transfecting H1299 cells with a pTRIPZ lentiviral-inducible vector expressing a Flag-p53 fusion protein and selecting the cells with puromycin. After 24 h of transfection, the cells were suspended, diluted and re-seeded to ensure single clone formation. More than 30 clones were selected, and the expression of p53 was evaluated in each clone by western blot with anti-p53 antibodies (DO-1).

Cells were transfected with plasmid DNA or siRNA using Lipofectamine 3000 (Invitrogen) according to the manufacturer’s protocol.

Protein purification
293T cells were transfected with plasmids containing Flag-p53, Flag-p300 or CBP-HA and cultured for 48 h. The cells were then harvested and lysed in BC500 buffer (20 mM Tris-HCl pH 7.3, 500 mM NaCl, 20% glycerol, 0.5% Triton X-100) with sonication. Anti-Flag M2 beads (for Flag-p53 and Flag-p300) or anti-HA beads (for CBP-HA) were incubated with the cell lysates overnight at 4°C. The beads were washed with BC100 buffer (20 mM Tris-HCl pH 7.3, 100 mM NaCl, 20% glycerol, 0.1% Triton X-100) three times, and the purified proteins were competitively eluted with Flag peptide (Sigma) or HA peptide (Sigma) in BC100 buffer.
western blot using anti-p53 (DO-1) or anti-pan β-hydroxybutyrylation-lysine (BHB-K) antibodies.

Similarly, p53 kbhb was determined in 293T cells cotransfected with both Flag-p53 and CBP-HA plasmids (at a ratio of 1:1) and treated with 10 mM BHB for different times to evaluate the kbhb activity of CBP. The Flag-p53 protein was purified as before and the purified protein was assayed by western blot using anti-p53 (DO-1) or BHB-K or anti-pan-acetylation-lysine (Ac-K) antibodies.

p53 kbhb and acetylation were evaluated in wild-type U2OS cells and HCT116 cells before and after treatment with 10 mM BHB for 24 h. The cells were lysed with RIPA + 0.05% SDS followed by sonication. Lysine β-hydroxybutyrylated and acetylated proteins were purified by immunoprecipitation (IP) with BHB-K and Ac-K antibodies, and p53 was detected by western blots using the anti-p53 antibody (DO-1) with ReliaBLOT® IP/Western Blot Reagent (Bethyl) to inhibit the signal of the Ig heavy chain interference.

Detection of p53 kbhb in mouse thymus
Six- to eight-week-old C57BL male mice were either fed a standard chow diet or fasted (with free access to water) for 48 h. The mice were euthanized, and their thymus cells were lysed with RIPA + 0.05% SDS followed by sonication. Lysine β-hydroxybutyrylated and acetylated proteins were purified by IP with BHB-K antibodies, and p53 was detected by western blots with antibodies against full-length p53 diluted in ReliaBLOT® IP/Western Blot Reagent (Bethyl) to inhibit the signal of the Ig heavy chain interference.

In vitro kbhb assay
The following reactions were prepared in buffer (20 mM HEPES (4-(2-hydroxyethyl)-1-piperazyineethanesulfonic acid), pH 8.0: 1 mM DTT (1,4-dithiothreitol); 1 mM PMSF (phenylmethylsulfonyl fluoride); 1 µg of p53 and 100 ng of CBP in 0.1 mM β-hydroxybutyrylation-CoA (BHB-CoA); 1 µg of p53, 100 ng of p300 and 0.1 mM BHB-CoA; or 1 µg of mono-nucleosome, 100 ng of CBP and 0.1 mM BHB-CoA. After incubation for 1 h at 30 °C, the reaction products were analyzed by western blot assays with BHB-K antibodies.

Mass spectrometry assay
Protein complexes were separated by SDS–PAGE and stained with GelCode Blue reagent (Pierce, 24592). The visible band was cut and digested with trypsin and then subjected to liquid chromatography mass spectrometry (LC-MS/MS) analysis.

Cell growth assay
One hundred and four U2OS cells were spread into six-well plates (three replicates were performed). Cell growth was monitored each day by staining the cells with 2% methylene blue in 50% ethanol for 15 min at room temperature. Stained cells were extracted with 1% SDS and absorbance at 600 nm was measured to quantify cell numbers.

EdU staining
U2OS cells were treated either with 10 µM Nutlin (Sigma) for 8 h, 10 mM BHB for 16 h, or 10 µM Nutlin for 8 h and 10 mM BHB for 16 h. Or they were treated either with 10 µM doxorubicin for 8 h, or with 10 mM BHB for 16 h, or with 10 µM doxorubicin for 8 h and 10 mM of BHB for 16 h.

The treated cells were then grown in the presence of 50 µM EdU for 2 h, fixed and permeabilized. EdU was used to visualize proliferating cells with a Click-iT® EdU Apollo Fluor® 567 Imaging kit. The cells were then counterstained with DAPI (4′,6-diamidino-2-phenylindole) and imaged on a confocal microscope. In all, 20 randomly selected fields were imaged. The number of EdU-positive and DAPI-stained cells were counted and the percentage of cells with EdU-positive labeling was calculated. The experiments were repeated three times. All results are expressed as the mean ± standard deviation. Analysis of variance was performed using Student’s t test to determine the statistical significance of differences among the groups.

Apoptosis
HCT116 cells were treated with either 10 µM Nutlin for 8 h, 10 mM BHB for 16 h, or 10 µM Nutlin for 8 h and 10 mM BHB for 16 h, and apoptotic cells were identified using a FITC-Annexin V Staining kit following the manufacturer’s instructions.

Six- to eight-week-old C57BL male mice (five mice per group) were either fed a standard chow diet or fasted with free access to water for 48 h. The mice were treated with 12.5 Gy of γ-irradiation and euthanized 4 h later. Fed mice were used as controls. Thymus cells were obtained from all four groups. Apoptotic cells stained with FITC-conjugated Annexin V and necrotic cells stained with propidium iodide were analyzed by flow cytometry.

Reverse transcription quantitative PCR (RT-qPCR)
Total RNA was extracted from mouse thymus tissue using TRIzol (Invitrogen) according to the manufacturer’s protocol. Two micrograms of total RNA was reverse-transcribed into cDNA using SuperScript III First-Strand Synthesis SuperMix (Invitrogen). The relative expression level of each target gene was measured by qPCR and normalized to the level of actin. We focused on genes targeted by p534,8. The primers used are listed in Supplementary Table S1.
**p21 and PUMA expression in mice**

Six- to eight-week-old C57BL male mice (each group consisted of five mice) were either fed a standard chow diet or fasted with free access to water for 48 h. The mice were treated with 12.5 Gy of γ-irradiation and euthanized 4 h later. Untreated mice were used as controls. Thymus cells were lysed, and p21 and PUMA expression were analyzed by immunoblotting.

**Measurement of BHB in mouse serum**

Six- to eight-week-old C57BL male mice (each group consisted of five mice) were either fed a standard chow diet (five mice) or fasted with free access to water (five mice) for 48 h. Blood samples were taken from a tail vein for determination of blood BHB concentrations using a ketone meter (China, Alibaba).

**Mice**

Six- to eight-week-old C57BL male mice were licensed by Beijing Municipal Committee of Science and Technology. All mice were housed in a temperature-controlled room (22 ± 2 °C) with a light/dark cycle of 12 h/12 h. All animal experiments were performed according to Wenhui Zhao’s animal protocols (No. LA2018013) approved by the Animal Ethics Committee of the Peking University Health Science Center, China.

**Statistical analysis**

All the experiments were performed at least in triplicate, and all results are expressed as the mean ± standard deviation. All mouse data represent the average of results obtained in five 6- to 8-week-old male mice. Analysis of variance was performed using the Student’s t test to determine the statistical significance of differences among the groups.

**Results**

**p53 Kbhb occurs in cells in the presence of BHB and in the thymus of fasted mice**

To explore whether Kbhb occurs in p53, first, we purified and enriched this protein from 293T cells expressing Flag-tagged p53 and treated with BHB, pyruvate or glutamine. Immunoblot analysis was performed with anti-p53 and anti-pan β-hydroxybutyrylation-lysine antibodies (BHB-K), and the results showed that the purified p53 was recognized by both antibodies in cell lysates from cells treated with BHB but not in those from cells treated with pyruvate or glutamine, thus suggesting that p53 is modified by Kbhb in the presence of BHB, but not in the presence of pyruvate or glutamine (Fig. 1a).

Then, we assessed whether Kbhb occurs in endogenous p53 in U2OS cells whose p53 wild-type and signal pathway are complete. To this end we purified and enriched the Kbhb proteins from BHB-treated or -untreated U2OS cells by IP using the BHB-K antibody and the p53 protein was detected by western blot. As shown in Fig. 1b, the levels of p53 were notably higher in Kbhb-enriched lysates from BHB-treated cells than in those of untreated cells, while the levels of p53 remained unchanged in total cell lysates regardless of the treatment (Fig. 1b). This result was further confirmed in HCT116 cells, which are another kind of cells with wild-type p53 and a complete p53 signal pathway (Fig. 1c).

Finally, we assessed whether the cellular p53 Kbhb levels increase in response to high levels of BHB under physiological conditions. To this end, we determined p53 Kbhb in the thymus tissue of C57BL mice that were fed a normal chow diet or subjected to 48 h of fasting (supplied with water only). Serum BHB concentrations were higher sevenfold in the fasted mice than in the controls fed a normal diet (Fig. 1d), same as the literature described13. In addition, the levels of p53 were substantially higher in thymus cell lysates from fasted mice enriched by immunoprecipitation with the BHB-K antibody than in those from normal-fed mice (Fig. 1e). By contrast, the levels of p53 in total cell lysates were similar regardless of the diet (Fig. 1e).

Together, our results indicate that p53 undergoes Kbhb.

**p53 Kbhb occurs at lysines 120, 319, and 370**

To confirm the presence of Kbhb in p53 and determine the site of Kbhb, we purified Flag-p53 from transfected 293T cells that were treated with BHB, and analyzed the purified protein by HPLC-MS/MS. The mass spectrometry data showed that there was a mass shift at the lysine 120 residue of the p53 peptide, LGFLHSGTAKBHBSVTCTYSPACAK, which indicated that kbhb had occurred at lysine 120 (Fig. 1f). The mass spectrometric analysis also revealed that the lysine residues 319 and 370 were also modified (Fig. 1g, h). To validate these findings, we transfected 293T cells with plasmids expressing Flag-tagged p53 proteins with one or all three lysines mutated to arginine (120R/p53, K319R/p53, K370R/p53, and K120, K319,K370R/p53 (3KR p53), respectively) and we incubated the cells in the presence of BHB. Western blot analysis of the purified p53 using BHB-K antibodies showed that the signal was lower in K319R mutant and completely disappeared in the triple mutant (Fig. 1i), suggesting that the kbhb modification sites were at lysines 120, 319, and 370. Together, our results indicate that p53 undergoes kbhb at these three lysine residues.

**p53 Kbhb is catalyzed by CBP**

In addition to lysine acetylation, it was recently shown that various short-chain lysines undergo acylation in core histones, including lysine propionylation, butyrylation, 2-hydroxyisobutyrylation, 3-hydroxybutyrylation, crotonylation, malonylation, succinylation, and glutarylation13,25–29.
It is well-known that CBP/p300 is a histone acetyltransferase that acetylates p53 at K98 and K10130, K16431 and also six lysines of the C-terminal region4,32–35. Moreover, p300 was recently identified as a histone butyryltransferase that catalyzes histone butyrylation33,34. To test the possibility that CBP is a β-hydroxybutyryltransferase that catalyzes the kbhb of p53, we first investigated whether kbhb occurs in CBP. Interestingly, when purifying and exploring the Kbhb proteins from U2OS and HCT116 p53+/+ cell lines by IP using the BHB-K antibody, we can clearly detect the presence of CBP/p300 in 293T cells treated with 10 mM BHB. Western blot analysis of p53 by DO-1 antibodies as in (b). d The BHB in mouse serum were measured. Mice were fasted for 48 h or fed with a normal diet. Blood samples were taken from a tail vein for determination of blood BHB concentrations using a ketone meter. e Kbhb modification of endogenous p53 in mice thymus tissue. Thymus cell lysates of mice fasted for 48 h or fed with a normal diet were IP with BHB-K antibodies. Western blot analysis of p53 with anti-full-length p53 antibodies as in (b). f–h Mass spectrometry analysis identified p53-derived peptides containing β-hydroxybutyrylated Lys-120, Lys-319, and Lys-370. p53 purified from 293T cells transfected with plasmid DNA expressing Flag-p53 and treated with 10 mM BHB for 24 h was analyzed by HPLC-MS/MS. Annotated MS/MS spectra of peptides LGFLHSGTAKSVTCTYSPALMK (derived from amino acids 111–132, f), ALNTSSSPQPKK (derived from amino acids 307–320, g) and AHSSSHLKSK (derived from amino acids 364–372, h) was showing as b- and y-ion coverage. i Effect of lysine-to-arginine mutation on p53 kbhb. Western blot analysis using BHB-K of wild-type and mutant Flag-p53 expressed in 293T cells treated with 10 mM BHB for 24 h.
blot analysis with BHB-K antibody showed that the levels of p53 Kbhb increased over time and in the presence of CBP (Fig. 2a). These results suggest that CBP might be the β-hydroxybutyryl-transferase that catalyzes p53 kbhb.

To further confirm whether the role of CBP on p53 kbhb, we assessed p53 kbhb and acetylation in Flag-p53-expressing 293T cells transfected with plasmids expressing wild-type CBP or CBP with various mutations that have been associated with a loss of CBP’s p53 acetyltransferase activity in lymphomas. We hypothesized that mutations in CBP might modulate its ability to act as a β-hydroxybutyryl-transferase to catalyze the kbhb of p53. We transected 293T cells with plasmids expressing Flag-tagged p53, wild-type CBP, or CBP with various mutations that are observed in lymphomas. Flag-p53 purified from the 293T cells treated with BHB and two deacetylase inhibitors was analyzed by western blot using antibodies that recognize the acetylation of p53 K101, K164, or the C-terminal lysines, pan-acetylation of lysine (Ac-K), as well as with BHB-K. The results showed that all of the cells transected with CBP mutation-containing plasmids lost their ability to β-hydroxybutyrate p53 (panel BHB-K in Fig. 3b), while the K1320R mutant CBP maintained its ability to acetylate K101, K164 and the C-terminal region of p53. K1240R CBP, D1453R CBP, Y1482H CBP and H1487Y CBP still acetylated p53 at its C-terminal region, and only Y1450C CBP, Y1503D CBP and Y1503F CBP lost their ability to acetylate p53 (Fig. 2b). These results further support a role for CBP in p53 kbhb.

Next, we investigated the effect of kbhb on p53 activity. To this end, HCT116 cells (Fig. 3c, d). These results were more evident when CBP was overexpressed in the presence and absence of BHB in 293T cells. The levels of p53 acetylation in CBP-overexpressing cells were remarkably lower in BHB-treated cells than in untreated cells (Fig. 3e). These results suggested that KBH treatment induced the β-hydroxybutyrylation of p53 and preferentially interfered with the acetylation of p53 C-terminal in cells.

Since posttranslational modification of p53 is known to affect its activity, we next investigated whether p300 could β-hydroxybutyrate p53 in vitro using purified p53 and CBP proteins and BHB-CoA as a co-factor (Fig. 2c). We found that a kbhb signal was only detected for p53 when wild-type CBP and p53 were incubated in the presence of BHB-CoA, but not when a mutant CBP was used (lanes 4 vs. 8) or when the 3KR p53 mutant was used (lanes 4 vs. 6). We found that a kbhb signal was detected for CBP when wild-type (lanes 3, 4, and 6), but not mutant (lanes 7 and 8), CBP was incubated with BHB-CoA, no matter with or without p53 or 3KR p53, which shows that CBP catalyzes itself with β-hydroxybutyryl-transferase activity, similar to CBP acetylation (Fig. 2c).

To better understand the potential role of CBP on the β-hydroxybutyrylation of p53, two different siRNA oligos were used to knock down the CBP in U2OS cell lines, and we found that CBP protein expression level was significantly reduced compared to the negative control. Consistent with the expected results, the CBP knockdown expression caused a lower level of the β-hydroxybutyrylation of p53 (Fig. 2d). Those results further supported that CBP can β-hydroxybutyrate p53.

Because CBP and p300 are very similar protein sequences and their structure even functions, and both are acetyltransferases, we tested whether p300 could β-hydroxybutyrate p53. We set up an in vitro assay using purified p53 and p300 proteins and BHB-CoA as a cofactor (Fig. 2e). The results demonstrated that p300 can act as a β-hydroxybutyryl-transferase for p53 and p300 themselves, and works similar to CBP, which are the same as their acetyltransferase activity (Fig. 2d).

Together, our results indicate that p53 is a bona fide kbhb substrate of CBP/p300 both in vivo and in vitro.

**Kbhb reduces p53 acetylation and activation**

We identified p53 Kbhb, in addition to p53 lysine acetylation, both of which are short-chain lysine acylations. Because the same enzyme (CBP) catalyzes both types of p53 modification, and because kbhb affects the acetylation of histones in previously described cases, we wanted to study whether p53 Kbhb might affect p53 acetylation under different conditions. To investigate this, Flag-p53-expressing 293T cells were treated with BHB and/or an inhibitor of the deacetylase SIRT1 (Ex527) and acetylation and kbhb were assessed in purified p53 by immunoblotting with Ac-K and BHB-K antibodies, respectively (Fig. 3a, b). The results showed that the levels of p53 acetylation were lower in the presence of BHB when p53 kbhb was detected (Fig. 3a, b). Similar results were obtained in HCT116 cells (Fig. 3c, d). These results were more evident when CBP was overexpressed in the presence and absence of BHB in 293T cells. The levels of p53 acetylation in CBP-overexpressing cells were remarkably lower in BHB-treated cells than in untreated cells (Fig. 3e). These results suggested that BHB treatment induced the β-hydroxybutyrylation of p53 and preferentially interfered with the acetylation of p53 C-terminal in cells.

Liu et al. *Cell Death and Disease* (2019) 10:243

Official journal of the Cell Death Differentiation Association
induce p53 expression and/or BHB. As expected, doxycycline treatment induced p53 expression and that of the p53-regulated genes p21 and PUMA at the protein level. However, the protein levels of p21 and PUMA were much lower when the cells were coincubated with BHB (Fig. 3g).

Last, we investigated the effect of kbhb on p53 activity under genotoxic stress by detecting p21 and PUMA expression in HCT116 cells treated with the DNA-damaging agent doxorubicin and/or BHB (Fig. 3h). Similar results were obtained as in the induction of p53-expressing H1299 cells; doxorubicin treatment activated p53 and upregulated genes p21 and PUMA at the protein level. However, the protein levels of p21 and PUMA were much lower when the cells were coincubated with BHB (Fig. 3h).

Similar results of Khb on endogenous p53 activity, nutlin, an MDM2 inhibitor, was used to increase the level of endogenous p53 protein in U2OS. The results showed that nutlin can significantly increase the level of endogenous p53 protein and increase the protein expression levels of p21 and PUMA (line 3), but the protein expression levels of p21 and PUMA are significantly downregulated in combination with BHB treatment (line 4, Fig. 3i). These results show that the β-hydroxybutyrylation of p53 can alter the acetylation of p53 and affect the transcriptional activity of p53 on its target gene.

**p53 cell growth arrest and apoptosis-inducing functions are attenuated in the BHB-treated cells**

Since p53 is involved in the regulation of cell growth and cell apoptosis and this is particularly important in tumor development, we decided to study how kbhb affected the cell growth arrest function and cell apoptosis function of p53. To this end we monitored the cell growth of U2OS cells treated with BHB and/or Nutlin, a compound that prevents MDM2 from degrading p53, thus...
resulting in p53 stabilization and activation. As expected, Nutlin-treated cells grew more slowly than control cells or cells treated with BHB alone (Fig. 4a). By contrast, cells treated with both Nutlin and BHB grew at a similar rate to control cells and cells treated with BHB only (Fig. 4a). Similar results were obtained in U2OS cells treated with Nutlin and/or BHB, after measuring cell growth using EdU staining (Fig. 4b).

We also assayed cell proliferation by EdU staining in U2OS cells treated with BHB and/or the DNA-damaging agent doxorubicin that damage DNA to induce p53 activation and, therefore, cell growth arrest. The results
showed that the percentage of EdU-positive cells was lower when cells were treated with doxorubicin, relative to untreated controls, as expected. However, when cells were treated with both doxorubicin and BHB, the percentage of EdU-positive cells increased, relative to cells treated with doxorubicin alone (Fig. 4c). Together, these results indicate that under p53 kbhb-inducing conditions, the cell growth arrest function of p53 is attenuated.

In addition, we investigated the effect of kbhb on the apoptosis-inducing function of p53 in HCT116 cells treated with Nutlin (Fig. 4d). The results showed a small but significant reduction in the apoptosis of HCT116 cells in the presence of BHB compared to that of cells treated with Nutlin alone (Fig. 4d), supporting a reduction of p53 activity under kbhb-inducing conditions.
**Induction of p53-regulated genes is reduced in tissues of fasted mice under genotoxic conditions**

To explore the effect of p53 Kbhb in vivo, we analyzed thymus tissues obtained from fasted C57BL mice under genotoxic conditions. Mice were fed with a normal chow diet or subjected to 48 h of fasting (supplied with water only), and were then γ-irradiated to damage their DNA, therefore inducing p53 activation. Mice blood BHB was increased about sevenfold of fasted mice than fed, to induce p53 Kbhb (Fig. 1d, e). p53 activity was monitored by following the expression of its downstream target genes PUMA and p21 in the thymus at the protein level. In nonirradiated mice, PUMA protein levels were lower in fasted mice than in fed mice, while the levels of p21 were below the limit of detection (Fig. 5a). By contrast, p21 could be detected in the γ-irradiated group where the levels of both p21 and PUMA were higher than in the nonirradiated group, regardless of whether the mice were fed or fasted (Fig. 5a). In addition, within the mice exposed to γ-irradiation, the levels of p21 and PUMA were lower in the fasted than in the fed mice (Fig. 5a).

Expression of p21 and PUMA was also assessed at the mRNA level in the thymus tissues of the fasted and fed mice exposed or unexposed to γ-irradiation. The expression of these genes was significantly increased by γ-irradiation (p ≤ 0.001), as expected. However, the extent of this increase was much larger in the fed than in the fasted mice (Fig. 5b). Similar results were obtained for the p53 target gene Bax (Fig. 5b).

To confirm that the expression pattern changes of p21 and PUMA between the fasted and fed mice were caused by the β-hydroxybutyrylation of p53, both β-hydroxybutyrylation and acetylation levels of p53 in the mice were examined. We found that IR can cause a significant increase in p53 protein levels in the thymus, no matter normal fed or fasted treatment; while the expression level of CBP was not significantly altered in all the treatments (Fig. 5c). Furthermore, a fasted treatment in IR mice resulted in a significant reduction in the level of acetylation of p53 compared to the normal diet group (Fig. 5c, lines 4 vs. 3), and in the no-irradiated mice, the same fasted treatment resulted in a slight increase in the level of acetylation of p53 (Fig. 5c, lines 2 vs. 1). To conclude, we found that starvation results in increasing BHB levels in plasmas (Fig. 1d), leading to an increase in the β-hydroxybutyrylation of p53 in the thymus with a decrease in the acetylation of p53, which causes a change in the expression pattern of p21 and PUMA, which is consistent with the in vitro data (Fig. 3).

To further validate the effect of p53 Kbhb, we next extended to investigate the expression of additional p53 target genes identified in the literature. The results showed that in fed mice, as expected, all the expression of all the assessed genes considerably increased by γ-irradiation (Fig. 5d, e). However, the results showed that in all the cases the induction by γ-irradiation was lower in fasted mice compared to fed mice with statistically significant differences (Fig. 5d, e).

Finally, we investigated the effects of γ-irradiation on the apoptosis of cells from the thymus tissues of fed and fasted mice (Fig. 5f). Nonirradiated mice, both fed and fasted, had significantly fewer apoptotic cells in their thymus tissues than did the fed and fasted mice exposed to 12.5 Gy of γ-irradiation (Fig. 5f). In addition, in nonirradiated mice, there were fewer apoptotic cells in the thymus of the fed mice relative to the fasted mice (Fig. 5f). By contrast, in γ-irradiated mice the percentage of apoptotic cells was lower in fasted than in fed mice (Fig. 5f).

Overall, these results indicate that under Kbhb conditions there is a reduced genotoxic-induced p53 activation resulting in reduced expression of p53-regulated genes and reduced cell apoptosis.

**Discussion**

p53 is an essential tumor suppressor. The TP53 gene (in mice it is Trp53 gene) has long been recognized as a vitally important tumor suppressor gene because it is mutated and inactivated in more than 80% of human cancer cases. The p53 protein is one of the most widely studied transcription factors. It has been found that p53 activity is finely tuned by the posttranslational modifications such as acetylation, methylation, phosphorylation, ubiquitination, sumoylation, and neddylation.

The major ketone bodies are BHB and acetoacetate, which can be converted into each other and trace amounts of acetone. Ketone bodies are predominantly formed in the liver by acetyl coenzyme A, which degrades fatty acids via β-oxidation. In addition to serving as an energy source, ketone bodies are also recognized as factors that fulfill signaling roles in cellular homeostasis (reviewed in refs. 12–17). BHB plays signaling roles by a mechanism that BHB induces Kbhb, which is a novel histone posttranslational modification.

Kbhb has been described only in histone proteins. Our prior evidence from mass spectrometry analysis data suggested that p53 may be β-hydroxybutyrylated. Therefore, here we studied p53 Kbhb. p53 Kbhb is an entirely novel discovery.

We have found for the first time that p53 can be modified by Kbhb in the presence of BHB and that this modification is catalyzed by the acetyltransferase CBP. In particular, our results demonstrate that p53 Kbhb occurs in cells treated with BHB and in the thymus tissues of fasted mice, in which the serum concentrations of BHB increased. In addition, we found that in the presence of BHB the levels of p53 acetylation, which correlate with p53 activity, were reduced in favor of p53 Kbhb.
Consistent with these results, our findings show that the upregulation of p53 target genes by genotoxic stress was lower in fasted mice than in fed mice. In addition, apoptosis and cell growth arrest mediated by p53 activated by DNA damage or protected from degradation by Nutlin, were decreased by BHB treatment.

Ketone bodies, such as BHB, are reported to play a role in cancer biology \(^{21-24}\); however, their specific role remains to be elucidated. It has been reported that ketone bodies reduced pancreatic cancer growth in mouse xenograft models \(^ {21} \), and decreased the proliferation and viability of the highly metastatic VM-M3 cells, and prolonged the survival of VM-M3 xenograft mice \(^ {22} \). On the contrary, the ketone body acetooacetate has been found to drive tumor cell proliferation and growth in melanoma through a cellular signaling pathway involving MEK-ERK signaling \(^ {23} \). The use of ketogenic diets and calorie restriction also have therapeutic effects in human and mouse brain tumors \(^ {24} \). But it has been recently reported that ketogenic diets only changed the flora of bacterium in the digest system, not ketone bodies to contribute the therapeutic effects \(^ {36} \). Our findings show that p53 Kbhb is
induced by BHB and that kbbh attenuates p53 activity. Since p53 is an important tumor suppressor protein, attenuation of its activity in the presence of BHB might partially explain its role of ketone bodies in cancer. The inconsistency of the previous report may be because that p53 mutation has not been taken into consideration.

Our findings show that BHB induces p53 kbbh. Fatty acid metabolism via β-oxidation produces acetyl coenzyme A to synthesize ketone bodies in the liver, which spread to the whole body. Therefore, we can view from a different angle the relationship between fatty acids and cancer. We paved a new way to explore the function of fatty acids metabolism in cancer, which need to be studied deeply in the future.

We found that CBP β-hydroxybutyryltransferase histones and p53, in addition to acetylating histones and p533–9. From our point of view, this may be caused by a sharp rise in the level of BHB-CoA in cells treated with BHB. This concentration advantage induces CBP to catalyze the β-hydroxybutyrylation of p53, which in turn affects CBP to catalyze the acetylation of p53. Thus, CBP appears to be a flexible enzyme that might play important roles in acyla-tion, which need to be further investigated in future studies.

These data suggest that CBP β-hydroxybutyryltransferase activity is more strictly limited than is acetyltransferase activity on p53. However, this might be because our BHB-K antibody is not as sensitive as detecting lower levels of p53 kbbh as are other site-specific acetylation antibodies, such as those for K101, K164 and the C-terminal region of p53. This issue requires further investigation with site-specific BHB-K antibodies.

Acknowledgements

We are grateful to Center of Medical and Health Analysis, Peking University for confocal microscopy. Wenhui Zhao was supported by National Natural Science Foundation of China Grant (No. 85141044).

Author details

1Department of Biochemistry and Molecular Biology, Beijing Key Laboratory of Protein Posttranslational Modifications and Cell Function, Peking University Health Science Center, 38 Xueyuan Road, 100191 Beijing, China. 2Department of Biomedical Informatics, Beijing Key Laboratory of Protein Posttranslational Modifications and Cell Function, Peking University Health Science Center, 38 Xueyuan Road, 100191 Beijing, China. 3Department of Laboratory Animal Science, School of Basic Medical Sciences, Beijing Key Laboratory of Protein Posttranslational Modifications and Cell Function, Peking University Health Science Center, 38 Xueyuan Road, 100191 Beijing, China. 4Department of Pharmacology I, Shanghai Institute of Materia Medica, 555 Zu Zhong Zhi Road, Zhang Jiang Hi-Tech Park, 201203 Pudong, Shanghai, China. 5Ben May Department of Cancer Research, The University of Chicago, Chicago, IL, USA. 6Institute for Cancer Genetics, and Department of Pathology and Cell Biology, College of Physicians and Surgeons, Columbia University, 1130 St. Nicholas Avenue, New York, NY 10032, USA

Conflict of interest

The authors declare that they have no conflict of interest.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

accompanies this paper at (https://doi.org/10.1038/s41419-019-1463-y).

Received: 22 October 2018 Revised: 8 January 2019 Accepted: 1 February 2019

Published online: 11 March 2019

References

1. Olivier, M., Holtstein, M. & Hainaut, P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb. Perspect. Biol. 2, a001008 (2010).
2. Kruse, J. P. & Gu, W. Modes of p53 regulation. Cell 137, 609–622 (2009).
3. Vousden, K. H. & Prives, C. Blinded by the light: the growing complexity of p53. Cell 137, 413–431 (2009).
4. Wang, D. et al. Acetylation-regulated interaction between p53 and SET reveals a widespread regulatory mode. Nature 538, 118–122 (2016).
5. Levine, A. J. & Oren, M. The first 30 years of p53: growing ever more complex. Nat. Rev. Cancer 9, 749–758 (2009).
6. Feng, Z., Lin, M. & Wu, R. The regulation of aging and longevity: a new and complex role of p53. Genes Cancer 2, 443–452 (2011).
7. Jiang, L., Hickman, J. H., Wang, S. J. & Gu, W. Dynamic roles of p53-mediated metabolic activities in ROS-induced stress responses. Cell Cycle 14, 2881–2885 (2015).
8. Jiang, L. et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature 520, 57–62 (2015).
9. Robinson, A. M. & Williamson, D. H. Physiological roles of ketone bodies as substrates and signals in mammalian tissues. Physiol. Rev. 60, 143–187 (1980).
10. Laffel, L. Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes. Diabetes Metab. Res. Rev. 15, 412–426 (1999).
11. Cahill, G. F. Jr. Fuel metabolism in starvation. Annu. Rev. Nutr. 26, 1–22 (2006).
12. Shimazu, T. et al. Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science 339, 211–214 (2013).
13. Xie, Z. et al. Metabolic regulation of gene expression by histone lysine β-hydroxybutyrylation. Mol. Cell 62, 194–206 (2016).
14. Youn, Y. H. et al. The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat. Med. 21, 263–269 (2015).
15. Marosi, K. et al. 3-Hydroxybutyrate regulates energy metabolism and induces BDNF expression in cerebral cortical neurons. J. Neurochem. 139, 769–781 (2016).
16. Skelman, S. F. et al. Exercise promotes the expression of brain derived neurotrophic factor (BDNF) through the action of the ketone body β-hydroxybutyrate. eLife 5, e15092 (2016).
17. Roberts, M. N. et al. A ketogenic diet extends longevity and healthspan in adult mice. Cell Metab. 26, 539–546.e5 (2017).
18. Rojas-Morales, P., Tapia, E. & Pedraza-Chaverri, J. β-Hydroxybutyrate: a signaling metabolite in starvation response? Cell Signal. 28, 917–923 (2016).
19. Puchalska, P. & Crawford, P. A. Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics. Cell Metab. 25, 262–264 (2017).
20. Newman, J. C. & Verdin, E. β-Hydroxybutyrate: a signaling metabolite. Annu. Rev. Nutr. 37, 51–76 (2017).
21. Shukla, S. K. et al. Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia. Cancer Metab. 2, 18 (2014).
22. Poit, A. M., Aci, C., Arnold, P., Seyfried, T. N. & D’Agostino, D. P. Ketone supplementation decreases tumor cell viability and prolongs survival of mice with metastatic cancer. Int. J. Cancer 135, 1711–1720 (2014).
23. Kang, H. B. et al. Metabolic rewiring by oncogenic BRAF V600E links keto-metabolism to BRAF-MEK1 signaling. Cell Metab. 21, 345–358 (2015).
24. Meidenbauer, J. J., Mukherjee, P. & Seyfried, T. N. The glucose ketone index calculator: a simple tool to monitor therapeutic efficacy for metabolic management of brain cancer. Nutr. Metab. (Lond.) 12, 12 (2015).
25. Chen, Y. et al. Lysine propionylation and butyrylation are novel post-translational modifications in histones. Mol. Cell. Proteom. 15, 262–264 (2016).
26. Dai, L. et al. Lysine 2-hydroxyisobutyrylation is a widely distributed active histone mark. Nat. Chem. Biol. 10, 365–370 (2014).
27. Tan, M. et al. Lysine glutarylation is a protein posttranslational modification regulated by SIRT3. Cell Metab. 19, 605–617 (2014).

Official journal of the Cell Death Differentiation Association
28. Tan, M. et al. Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification. Cell 146, 1016–1028 (2011).
29. Xie, Z. et al. Lysine succinylation and lysine malonylation in histones. Mol. Cell. Proteom. 11, 100–107 (2012).
30. Wang, S. J. et al. Acetylation is crucial for p53-mediated ferroptosis and tumor suppression. Cell Rep. 17, 366–373 (2016).
31. Tang, Y., Zhao, W., Chen, Y., Zhao, Y. & Gu, W. Acetylation is indispensable for p53 activation. Cell 133, 612–626 (2008).
32. Gu, W. & Roeder, R. G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 22, 595–606 (1997).
33. Kaczmarska, Z. et al. Structure of p300 in complex with acyl-CoA variants. Nat. Chem. Biol. 13, 21–29 (2017).
34. Goudarzi, A. et al. Dynamic competing histone H4 K5K8 acetylation and butyrylation are hallmarks of highly active gene promoters. Mol. Cell 62, 169–180 (2016).
35. Pasqualucci, L. et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 471, 189–195 (2011).
36. Christine, A. et al. The gut microbiota mediates the anti-seizure effects of the ketogenic diet. Cell 173, 1728–1741.e13 (2018).